Eli Lilly (LLY)
(Delayed Data from NYSE)
$820.34 USD
+5.28 (0.65%)
Updated May 31, 2024 04:04 PM ET
After-Market: $819.89 -0.45 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Brokerage Reports
Eli Lilly and Company [LLY]
Reports for Purchase
Showing records 41 - 60 ( 430 total )
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended August 18.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 82123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 81123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 8123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 72123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 71123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended June 30.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended June 2.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended April 7.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 41123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 4123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Biotechnology- Weekly Retail Sales Tracker for Solid Tumors - Week Ended March 24.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended March 17.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D